Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Edward Garon, MD, MS
Conference Coverage
Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?
05/15/2024
Edward Garon, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates...
05/15/2024
Oncology
Corey Langer, MD
Conference Coverage
The Case Against Antibody Drug Conjugates for Patients With Lung Cancers
05/15/2024
Corey Langer, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.
At the Great Debates and Updates...
05/15/2024
Oncology
Edward Garon, MD, MS
Conference Coverage
Should Pemetrexed Be Continued in Patients Who Receive the KEYNOTE-189 Regimen?
05/14/2024

Featuring Edward Garon, MD, MS

Featuring Edward Garon, MD, MS ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that pemetrexed maintenance therapy should eventually be stopped.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that pemetrexed maintenance therapy should eventually be stopped.
At the Great Debates and Updates...
05/14/2024
Oncology
Corey Langer, MD
Conference Coverage
Advantages to Continuing Pemetrexed as Maintenance Therapy in the KEYNOTE-189 Regimen
05/14/2024
Corey Langer, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.
At the Great Debates and Updates...
05/14/2024
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Use of Liquid Biopsies to Reduce Time to Treatment for Patients With Lung Cancer
05/07/2024

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that upfront liquid biopsies are an essential part of the initial patient workup.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that upfront liquid biopsies are an essential part of the initial patient workup.
At the Great Debates and Updates...
05/07/2024
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Discussing the Need of Adjuvant Treatment After Neoadjuvant in Early Stage Lung Cancer
05/06/2024

Featuring Christian Rolfo, MD, PhD

Featuring Christian Rolfo, MD, PhD ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.
At the Great Debates and Updates...
05/06/2024
Oncology
Balazs Halmos, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Exploring Optimal Treatment for Patients With STK-11– and KEAP-1–Mutated Lung Cancer
05/03/2024

Featuring Balazs Halmos, MD

Featuring Balazs Halmos, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Balazs Halmos MD, discussed the addition of CTLA-4 inhibition in the treatment of STK-11– and KEAP-1–mutated lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Balazs Halmos MD, discussed the addition of CTLA-4 inhibition in the treatment of STK-11– and KEAP-1–mutated lung cancer.
At the Great Debates and Updates...
05/03/2024
Oncology
Rebecca Heist, MD, MPH, Massachusetts General Hospital
Conference Coverage
Targeted Therapies for Patients With Lung Cancer Exhibiting BRAF Mutations or MET Skipping Alterations
05/02/2024

Featuring Rebecca Heist, MD, MPH

Featuring Rebecca Heist, MD, MPH ...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.
At the Great Debates and Updates...
05/02/2024
Oncology
Koosha Paydary, MD, MPH, MSc, Rush University Medical Center
Conference Coverage
CTLA-4 Inhibitors for Patients With PD-L1–Negative/PD-L1<1% Lung Cancer
04/29/2024

Featuring Koosha Paydary, MD, MPH, MSc

Featuring Koosha Paydary, MD, MPH, MS...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Koosha Paydary, MD, MPH, MSc, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Koosha Paydary, MD, MPH, MSc, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1
At the Great Debates and Updates...
04/29/2024
Oncology
Charles Simone, MD
Conference Coverage
Addition of Stereotactic Body Radiation Therapy to Systemic Therapy Improves Outcomes Among Patients With Oligometastatic, Oligoprogressive NSCLC
04/28/2024

Featuring Charles Simone, MD

Featuring Charles Simone, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that adding SBRT to systemic therapy is a strong and effective way to treat patients with oligometastatic or oligoprogressive non-small...
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that adding SBRT to systemic therapy is a strong and effective way to treat patients with oligometastatic or oligoprogressive non-small...
At the Great Debates and Updates...
04/28/2024
Oncology
Jamie Chaft, MD, Memorial Sloan-Kettering Cancer Center
Conference Coverage
The Benefit of Perioperative Immunotherapy in Lung Cancer Treatment
04/28/2024

Featuring Jamie Chaft, MD

Featuring Jamie Chaft, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, argued in favor of both pre- and post-operative immunotherapy in the treatment of lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, argued in favor of both pre- and post-operative immunotherapy in the treatment of lung cancer.
At the Great Debates and Updates...
04/28/2024
Oncology
Charles Simone, MD
Conference Coverage
Non-Surgical Interventions for Patients With Stage 3 Non-Small Cell Lung Cancer
04/27/2024

Featuring Charles Simone, MD

Featuring Charles Simone, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates...
04/27/2024
Oncology
Christian Rolfo, MD, PhD
Videos
Using ctDNA to Monitor Patients With Lung Cancers
10/05/2023
At the Great Debates & Updates in Lung Cancer meeting, Chrisitian Rolfo, MD, PhD, discussed the use of ctDNA to monitor patients with lung cancers.
At the Great Debates & Updates in Lung Cancer meeting, Chrisitian Rolfo, MD, PhD, discussed the use of ctDNA to monitor patients with lung cancers.
At the Great Debates & Updates...
10/05/2023
Oncology
Karen Reckamp, MD
Videos
The Case for Chemotherapy Plus Immunotherapy for Patients With Low or Negative PD-L1
10/05/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Karen Reckamp, MD, debated in favor of using chemotherapy plus immunotherapy for patients with NSCLC and PD-L1 expressions of
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Karen Reckamp, MD, debated in favor of using chemotherapy plus immunotherapy for patients with NSCLC and PD-L1 expressions of
At the Great Debates & Updates...
10/05/2023
Oncology
Karen Reckamp, MD
Videos
Treatment Landscape for Patients With Metastatic NSCLC Without Actionable Mutations
10/05/2023
At the Great Debates & Updates in Lung Cancer Meeting in New York, Karen Reckamp, MD, gave an overview of the treatment landscape for patients with metastatic non-small cell lung cancers that do not have actionable mutations.
At the Great Debates & Updates in Lung Cancer Meeting in New York, Karen Reckamp, MD, gave an overview of the treatment landscape for patients with metastatic non-small cell lung cancers that do not have actionable mutations.
At the Great Debates & Updates...
10/05/2023
Oncology
Jamie Chaft, MD
Videos
The Case for Neoadjuvant Immunotherapy in Resectable NSCLC
10/05/2023
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of neoadjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of neoadjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates...
10/05/2023
Oncology
Jamie Chaft, MD
Videos
The Case for Immunotherapy Alone for Patients With PD-L1-High NSCLC in the First-Line Setting
09/29/2023
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of using immunotherapy alone in the first-line setting for patients with high PD-L1 expression and non-small cell lung cancer.
At the Great Debates & Updates meeting in New York, Jamie Chaft, MD, debated in favor of using immunotherapy alone in the first-line setting for patients with high PD-L1 expression and non-small cell lung cancer.
At the Great Debates & Updates...
09/29/2023
Oncology
Misako Nagasaka, MD, PhD
Videos
The Case for Lorlatinib in ALK-Positive NSCLC
09/28/2023
At the Great Debates & Updates in Lung Cancer meeting, Misako Nagasaka, MD, PhD, debated in favor of lorlatinib over alectinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).
At the Great Debates & Updates in Lung Cancer meeting, Misako Nagasaka, MD, PhD, debated in favor of lorlatinib over alectinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).
At the Great Debates & Updates...
09/28/2023
Oncology
Corey Langer, MD
Videos
How to Handle Elderly Patients and Those With Performance Status 2 NSCLC
09/28/2023
At the Great Debates & Updates in Lung Cancer meeting Corey Langer, MD, discussed the therapeutic landscape for underserved patients with non-small cell lung cancer — elderly patients, and patients with ECOG performance status 2.
At the Great Debates & Updates in Lung Cancer meeting Corey Langer, MD, discussed the therapeutic landscape for underserved patients with non-small cell lung cancer — elderly patients, and patients with ECOG performance status 2.
At the Great Debates & Updates...
09/28/2023
Oncology
Patrick Forde, MD
Videos
The Case for Adjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, debated in favor of adjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, debated in favor of adjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates...
09/26/2023
Oncology
Hossein Borghaei, DO, MS
Videos
Novel Checkpoint Inhibitor Combinations for Lung Cancer
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, discussed the development of novel combinations of checkpoint inhibitors to better treat patients with refractory lung cancers.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, discussed the development of novel combinations of checkpoint inhibitors to better treat patients with refractory lung cancers.
At the Great Debates & Updates...
09/26/2023
Oncology
Charles B. Simone II, MD
Videos
The Case for Prophylactic Cranial Irradiation in Small-Cell Lung Cancer
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Charles Simone, MD, debated in favor of prophylactic cranial irradiation when considering treatment options for patients with small-cell lung cancer.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Charles Simone, MD, debated in favor of prophylactic cranial irradiation when considering treatment options for patients with small-cell lung cancer.
At the Great Debates & Updates...
09/26/2023
Oncology
Lyudmila Bazhenova, MD
Videos
Management of BRAF-Mutated Non-Small Cell Lung Cancer
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.
At the Great Debates & Updates...
09/26/2023
Oncology
Hossein Borghaei, DO, MS
Videos
The Case for Using Immunotherapy for Patients With Low or Negative PD-L1
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, debated in favor of using immunotherapy among patients with non-small lung cancer and PD-L1 expressions of
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Hossein Borghaei, DO, MS, debated in favor of using immunotherapy among patients with non-small lung cancer and PD-L1 expressions of
At the Great Debates & Updates...
09/26/2023
Oncology
Natasha Leighl, MD
Videos
Targeted Therapies for MET-Dependent Lung Cancers
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, discussed advances in targeted therapies for patients with MET-dependent lung cancers.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, discussed advances in targeted therapies for patients with MET-dependent lung cancers.
At the Great Debates & Updates...
09/26/2023
Oncology
Natasha Leighl, MD
Videos
Primacy of Front-Line Checkpoint Inhibitors in Non-Small Cell Lung Cancer
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, FRCPC, FASCO, discussed the primacy of front-line checkpoint inhibitors in non-small cell lung cancer.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, FRCPC, FASCO, discussed the primacy of front-line checkpoint inhibitors in non-small cell lung cancer.
At the Great Debates & Updates...
09/26/2023
Oncology
Ignacio Wistbua, MD
Videos
Challenges and Opportunities of Biomarker Diagnostics in Lung Cancer
09/23/2023
At Great Debates & Updates in Lung Cancer, Ignacio Wistuba, MD, discussed the challenges and opportunities associated with biomarker diagnostics in lung cancer.
At Great Debates & Updates in Lung Cancer, Ignacio Wistuba, MD, discussed the challenges and opportunities associated with biomarker diagnostics in lung cancer.
At Great Debates & Updates in...
09/23/2023
Oncology
Deborah Doroshow, MD, PhD
Videos
RET, NTRK, NRG1, and ROS1 Fusions as Targets in Lung Cancer
09/23/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Deborah Doroshow, MD, PhD, discussed the importance of screening patients with lung cancer for RET, ROS1, NTRK, and NRG1 fusions.
At the Great Debates & Updates...
09/23/2023
Oncology
Ticiana Leal, MD
Videos
The Case for Alectinib in ALK-Positive NSCLC
09/22/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Ticiana Leal, MD, debated in favor of alectinib over lorlatinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Ticiana Leal, MD, debated in favor of alectinib over lorlatinib when considering treatment options for patients with ALK-positive non-small cell lung cancer (NSCLC).
At the Great Debates & Updates...
09/22/2023
Oncology
Daniel Gomez, MD, Memorial Sloan Kettering
Videos
The Case Against Prophylactic Cranial Irradiation for Patients With SCLC
06/15/2023
Daniel Gomez, MD, summarizes his argument against prophylactic cranial irradiation for patients with small-cell lung cancer, a stance he defended in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...
Daniel Gomez, MD, summarizes his argument against prophylactic cranial irradiation for patients with small-cell lung cancer, a stance he defended in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...
Daniel Gomez, MD, summarizes his...
06/15/2023
Oncology
Corey Langer, MD, Abramson Cancer Center
Videos
How to Handle Elderly Patients and Individuals With Performance Status 2 and NSCLC
06/14/2023
At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...
At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...
At the 2023 Great Debates and...
06/14/2023
Oncology
Rebecca Heist, MD, Massachusetts General Hospital, Boston, MA
Videos
Updates in the Treatment of Patients With Small Cell Lung Cancer
05/18/2023
At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Rebecca Heist, MD, discusses developments and advances in the treatment of small cell lung cancer.
At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Rebecca Heist, MD, discusses developments and advances in the treatment of small cell lung cancer.
At the 2023 Great Debates and...
05/18/2023
Oncology
Edward Garon, MD, University of California, Los Angeles
Videos
Immuno-Oncology Alone for Patients With Lung Cancer and High PD-L1 Expression
05/18/2023
At the Great Debates and Updates in Lung Cancer conference in Chicago, Illinois, Eddie Garon, MD, makes the case for immuno-oncology alone as the optimal course of treatment lung cancer with PD-L1 expression ≥50%.
At the Great Debates and Updates in Lung Cancer conference in Chicago, Illinois, Eddie Garon, MD, makes the case for immuno-oncology alone as the optimal course of treatment lung cancer with PD-L1 expression ≥50%.
At the Great Debates and Updates...
05/18/2023
Oncology
Patrick Forde, MD, Johns Hopkins Medical Institute, Baltimore, MD
Videos
Chemotherapy Plus Immuno-Oncology for Lung Cancer With High PD-L1 Expression
05/18/2023
At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Patrick Forde, MD, makes the case for chemotherapy plus immuno-oncology as the best treatment for patients with lung cancer who have a PD-L1 expression of ≥50%.
At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Patrick Forde, MD, makes the case for chemotherapy plus immuno-oncology as the best treatment for patients with lung cancer who have a PD-L1 expression of ≥50%.
At the 2023 Great Debates and...
05/18/2023
Oncology
Vinai Gondi, MD, Northwestern Medicine West Region, Warrensville, IL
Videos
Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer
05/18/2023
Vinai Gondi, MD, explains his position on prophylactic cranial irradiation for patients with small-cell lung cancer, a controversy he addressed in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...
Vinai Gondi, MD, explains his position on prophylactic cranial irradiation for patients with small-cell lung cancer, a controversy he addressed in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...
Vinai Gondi, MD, explains his...
05/18/2023
Oncology
Heather Wakelee, MD, Stanford University, Palo Alto, California
Videos
Frontline Treatment Options for Patients With EGFR-Mutated NSCLC
05/18/2023
Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.
Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.
Heather Wakelee, MD, discusses...
05/18/2023
Oncology
Helena Yu, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Videos
Combating Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Cancer
05/17/2023
At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.
At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.
At the 2023 Great Debates and...
05/17/2023
Oncology
Kim Norris, Lung Cancer Foundation of America
Videos
Understanding and Employing Patient Advocacy
05/16/2023
At the 2023 Great Debates and Updates conference in Chicago Illinois, Kim Norris, co-founder and president of the Lung Cancer Foundation of America, discussed the different types of patient advocacy and the effect advocacy can have on...
At the 2023 Great Debates and Updates conference in Chicago Illinois, Kim Norris, co-founder and president of the Lung Cancer Foundation of America, discussed the different types of patient advocacy and the effect advocacy can have on...
At the 2023 Great Debates and...
05/16/2023
Oncology
Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute
Videos
How to Handle Patients With PD-L1 >50% Non-Small Cell Lung Cancer
12/13/2022
Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.
Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.
Leena Gandhi, MD, PhD, discusses...
12/13/2022
Oncology
Mark Awad, MD, PhD, Dana-Farber Cancer Institute
Videos
Overcoming Resistance to Checkpoint Inhibitors in Lung Cancer
12/13/2022
Dr Mark Awad reviews his presentation at the 2022 Great Debates and Updates in Lung Cancer meeting in New York which focused on the management of patient resistance to checkpoint inhibitors.
Dr Mark Awad reviews his presentation at the 2022 Great Debates and Updates in Lung Cancer meeting in New York which focused on the management of patient resistance to checkpoint inhibitors.
Dr Mark Awad reviews his...
12/13/2022
Oncology
Lyudmila Bazhenova, MD, Professor of Medicine at the University of California, San Diego, California
Videos
Dabrafenib Plus Trametinib for Patients With BRAF-V600E Mutated Lung Cancer
12/02/2022
Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD, reviews the treatment options for BRAF mutations in lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD, reviews...
12/02/2022
Oncology
Edward Garon, MD, David Geffen School of Medicine - UCLA, Los Angeles, California
Videos
Pembrolizumab Monotherapy for Patients With HighPD-L1 Non-Small Cell Lung Cancer
12/02/2022
Edward Garon, MD, discusses the treatment of patients with non-small cell lung cancer and a PD-L1 expression of ≥50%, a topic he debated at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Edward Garon, MD, discusses the treatment of patients with non-small cell lung cancer and a PD-L1 expression of ≥50%, a topic he debated at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Edward Garon, MD, discusses the...
12/02/2022
Oncology
Lyudmila Bazhenova, MD
Videos
Differentiating Targets and Therapies for Patients With HER2-Mutant Lung Cancer
11/29/2022
Lyudmila Bazhenova, MD, University of California, San Diego, California, discusses the management and treatment of patients with HER2-mutated non-small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung...
Lyudmila Bazhenova, MD, University of California, San Diego, California, discusses the management and treatment of patients with HER2-mutated non-small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung...
Lyudmila Bazhenova, MD,...
11/29/2022
Oncology
Lyudmila Bazhenova, MD
Videos
Targeting and Treating MET-Dependent Lung Cancers
11/18/2022
Lyudmila Bazhenova, MD, discusses targeted therapy for MET-dependent lung cancers, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD, discusses targeted therapy for MET-dependent lung cancers, a topic she presented at the 2022 Great Debates & Updates in Lung Cancer meeting in New York.
Lyudmila Bazhenova, MD,...
11/18/2022
Oncology
Kristin Higgins, MD
Videos
Current and Emerging Treatments in Small Cell Lung Cancer
11/18/2022
Kristin Higgins, MD, provides an overview on the current and future treatment of small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancers meeting in New York.
Kristin Higgins, MD, provides an overview on the current and future treatment of small cell lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancers meeting in New York.
Kristin Higgins, MD, provides an...
11/18/2022
Oncology
Helena Yu, MD
Videos
EGFR TKIs for Curative Intent Among Patients With Early-Stage Non-Small Cell Lung Cancer
11/15/2022
Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Helena Yu, MD, discusses the...
11/15/2022
Oncology
David Cescon, MD, Princess Margaret Cancer Center
Videos
CDK4/6 Inhibitors Exhibit Similarities in Progression-Free Survival for Metastatic ER-Positive/HER2-Negative Breast Cancer
11/14/2022
David Cescon, MD, PhD, discusses the similarities and differences in CDK4/6 inhibitors for patients with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.
David Cescon, MD, PhD, discusses the similarities and differences in CDK4/6 inhibitors for patients with breast cancer, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.
David Cescon, MD, PhD, discusses...
11/14/2022
Oncology
Helena Yu, MD
Videos
EGFR: First Line, Second Line and Beyond in the Age of Osimertinib
11/07/2022
Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.
Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.
Helena Yu, MD, shares exciting...
11/07/2022
Oncology
Raj Veluswamy, MD, Icahn School of Medicine, New York
Videos
NTRK: Front-Line and Second-Line Treatment Options for Patients With NSCLC
10/15/2022
Rajwanth Veluswamy, MD, provides an overview of his presentation at Great Debates and Updates in Lung Cancer covering front-line and second-line treatment options for patients with NSCLC and NTRK fusions.
Rajwanth Veluswamy, MD, provides an overview of his presentation at Great Debates and Updates in Lung Cancer covering front-line and second-line treatment options for patients with NSCLC and NTRK fusions.
Rajwanth Veluswamy, MD, provides...
10/15/2022
Oncology
Kristin Higgins, MD, Winship Cancer Institute, GA
Videos
SRS and Other Local Ablative Strategies in Patients With NSCLC and Oligometastases
10/15/2022
Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.
Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.
Dr Kristin Higgins provides an...
10/15/2022
Oncology
Nasser Altorki, MD, Weill Cornell Medical College
Videos
Adjuvant Checkpoint Inhibitors in Resectable NSCLC
10/15/2022
Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Dr Nasser Altorki reviews his...
10/15/2022
Oncology
Corey Langer, MD, Director of Thoracic Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania
Videos
Immune Checkpoint Inhibitors Improve Treatment Outcomes in Malignant Pleural Mesothelioma
09/22/2022
Corey Langer, MD, provides an overview on the potential of immune checkpoint inhibitors for the treatment of malignant pleural mesothelioma, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an overview on the potential of immune checkpoint inhibitors for the treatment of malignant pleural mesothelioma, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an...
09/22/2022
Oncology
Corey Langer, MD, Director of Thoracic Oncology at the Abramson Cancer Center at the University of Pennsylvania
Videos
Potential Impact of Immune Checkpoint Inhibitors in Thymic Malignancies
09/22/2022
Corey Langer, MD, provides an overview on the potential for immune checkpoint inhibitors in the treatment of thymic malignancies, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an overview on the potential for immune checkpoint inhibitors in the treatment of thymic malignancies, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an...
09/22/2022
Oncology
Edward Garon, MD, MS, David Geffen School of Medicine, University of California Los Angeles
Videos
Dr Edward Garon on the Basics of Immunotherapy in Lung Cancer
09/14/2022
Edward Garon, MD, MS, provides an overview on the basics of immunotherapy for NSCLC and SCLC, a topic he presented at the virtual 2022 GDU Lung Cancers meeting.
Edward Garon, MD, MS, provides an overview on the basics of immunotherapy for NSCLC and SCLC, a topic he presented at the virtual 2022 GDU Lung Cancers meeting.
Edward Garon, MD, MS, provides...
09/14/2022
Oncology
Conference Coverage
Dr Chaft Discusses Ipilimumab plus Nivolumab for PD-L1-low NSCLC
11/16/2021
At the virtual 2021 Personalized Therapies in Thoracic Oncology meeting, Jamie E. Chaft, MD engaged in a stimulating debate regarding the use of ipilimumab plus nivolumab for treating PD-L1-low NSCLC, at the virtual 2020 Personalized...
At the virtual 2021 Personalized Therapies in Thoracic Oncology meeting, Jamie E. Chaft, MD engaged in a stimulating debate regarding the use of ipilimumab plus nivolumab for treating PD-L1-low NSCLC, at the virtual 2020 Personalized...
At the virtual 2021 Personalized...
11/16/2021
Oncology
Conference Coverage
Dr Chaft Presents Progress for Immune Checkpoint Inhibitors in NSCLC
10/07/2021
Dr Chaft presents progress for immune checkpoint inhibitors in the curative setting of neoadjuvant and adjuvant therapy in resectable NSCLC, and outcomes the role of immunotherapy for patients with early-stage lung cancer.
Dr Chaft presents progress for immune checkpoint inhibitors in the curative setting of neoadjuvant and adjuvant therapy in resectable NSCLC, and outcomes the role of immunotherapy for patients with early-stage lung cancer.
Dr Chaft presents progress for...
10/07/2021
Oncology
Conference Coverage
Dr Lin Shares Systemic Therapies to Overcome Resistance in ALK+ Lung Cancer
10/05/2021
Jessica J. Lin, MD, presents resistance mechanisms inevitable in developing clinical benefits in systemic therapies for patients with advanced ALK+ lung cancer and how to create combination strategies that can overcome disease progression.
Jessica J. Lin, MD, presents resistance mechanisms inevitable in developing clinical benefits in systemic therapies for patients with advanced ALK+ lung cancer and how to create combination strategies that can overcome disease progression.
Jessica J. Lin, MD, presents...
10/05/2021
Oncology
News
Dr Yu Shares Updates of Prevention Efforts in EGFR-Mutant Lung Cancer
10/05/2021
Helena Yu, MD, discusses updates of small cell histologic transformation in EGFR-mutant lung cancers at the virtual 2021 Personalized Therapies in Thoracic Oncology meeting.
Helena Yu, MD, discusses updates of small cell histologic transformation in EGFR-mutant lung cancers at the virtual 2021 Personalized Therapies in Thoracic Oncology meeting.
Helena Yu, MD, discusses updates...
10/05/2021
Oncology
Lyudmila Bazhenova, MD
Conference Coverage
Treatment Courses for Third Generation EGFR TKI Resistance in Lung Cancer
10/02/2021
At the virtual 2021 Personalized Therapies in Thoracic Oncology meeting Lyudmila Bazhenova, MD provided an overview of how to manage lung cancer patients with TKI-resistance.
At the virtual 2021 Personalized Therapies in Thoracic Oncology meeting Lyudmila Bazhenova, MD provided an overview of how to manage lung cancer patients with TKI-resistance.
At the virtual 2021 Personalized...
10/02/2021
Oncology
News
Angioinhibition in the Management of NSCLC
12/11/2020
Edward B. Garon MD, MS, engaged in a stimulating debate regarding the relevancy of angioinhibition in the management of NSCLC, particularly for EGFR-positive patients, at the virtual 2020 Personalized Therapies in Thoracic Oncology meeting.
Edward B. Garon MD, MS, engaged in a stimulating debate regarding the relevancy of angioinhibition in the management of NSCLC, particularly for EGFR-positive patients, at the virtual 2020 Personalized Therapies in Thoracic Oncology meeting.
Edward B. Garon MD, MS, engaged...
12/11/2020
Oncology
Conference Insider
Treatment Courses for ALK Resistance in NSCLC
11/21/2020
At the virtual 2020 Personalized Therapies in Thoracic Oncology meeting, Jonathan Goldman, MD, provided an overview of how to manage patients with ALK-resistance in non-small-cell lung cancer (NSCLC).
At the virtual 2020 Personalized Therapies in Thoracic Oncology meeting, Jonathan Goldman, MD, provided an overview of how to manage patients with ALK-resistance in non-small-cell lung cancer (NSCLC).
At the virtual 2020 Personalized...
11/21/2020
Oncology
News
Targeted Therapy Options for MET-Dependent Lung Cancer
11/20/2020
In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Alexander Drilon PhD, Memorial Sloan Kettering Cancer Center, New York, shared insight on MET-dependent lung cancer.
In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Alexander Drilon PhD, Memorial Sloan Kettering Cancer Center, New York, shared insight on MET-dependent lung cancer.
In a session presented at the...
11/20/2020
Oncology
Aaron Lisberg, MD, On Treatment Approaches for Oncogene-Driven NSCLC
Conference Insider
Aaron Lisberg, MD, On Treatment Approaches for Oncogene-Driven NSCLC
11/20/2020
Dr Lisberg discusses when to use checkpoint inhibitor therapy for targetable mutations in NSCLC, a recap of his presentation at the 2020 Personalized Therapies in Thoracic Oncology meeting.
Dr Lisberg discusses when to use checkpoint inhibitor therapy for targetable mutations in NSCLC, a recap of his presentation at the 2020 Personalized Therapies in Thoracic Oncology meeting.
Dr Lisberg discusses when to use...
11/20/2020
Oncology
The Future Role of Liquid Biopsies in Lung Cancer Detection
Debates and Roundtables
The Future Role of Liquid Biopsies in Lung Cancer Detection
10/06/2020
In the second installment of this roundtable discussion, experts sat down with Oncology Learning Network to discuss use of liquid biopsies to detect treatment resistance in lung cancer, areas for growth of the technology, and potential future...
In the second installment of this roundtable discussion, experts sat down with Oncology Learning Network to discuss use of liquid biopsies to detect treatment resistance in lung cancer, areas for growth of the technology, and potential future...
In the second installment of...
10/06/2020
Oncology
Clinical Use of Liquid Biopsies in Lung Cancer
Debates and Roundtables
Clinical Use of Liquid Biopsies in Lung Cancer
10/06/2020
Joshua Bauml, MD, Lyudamila Bazhenova, MD, Jarushka Naidoo, M.B.B.Ch, discuss evolution and utilization of liquid biopsies in NSCLC in part 1 of this virtual roundtable discussion.
Joshua Bauml, MD, Lyudamila Bazhenova, MD, Jarushka Naidoo, M.B.B.Ch, discuss evolution and utilization of liquid biopsies in NSCLC in part 1 of this virtual roundtable discussion.
Joshua Bauml, MD, Lyudamila...
10/06/2020
Oncology
News
Basics of Immunotherapy in SCLC
10/03/2020
In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Stephen V. Liu, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C, shared insight on immunotherapy treatment for SCLC. 
In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Stephen V. Liu, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C, shared insight on immunotherapy treatment for SCLC. 
In a session presented at the...
10/03/2020
Oncology
Conference Insider
Front-Line Therapy Options for the Treatment of EGFR + Lung Cancer
10/02/2020
At the virtual 2020 Personalized Therapies in Thoracic Oncology meeting, Gregory J. Riely, MD, PhD, provided an overview of the current front-line therapies for patients with EGFR+ lung cancer.
At the virtual 2020 Personalized Therapies in Thoracic Oncology meeting, Gregory J. Riely, MD, PhD, provided an overview of the current front-line therapies for patients with EGFR+ lung cancer.
At the virtual 2020 Personalized...
10/02/2020
Oncology
Lyudmila Bazhenova, MD, Talks About Immune-Related AEs in Lung Cancer
Videos
Lyudmila Bazhenova, MD, Talks About Immune-Related AEs in Lung Cancer
03/25/2020
Dr Bazhenova talks about the management of immune-related adverse events in patients with lung cancer.
Dr Bazhenova talks about the management of immune-related adverse events in patients with lung cancer.
Dr Bazhenova talks about the...
03/25/2020
Oncology
Remarkable Breakthroughs in the Treatment of Advanced NSCLC
Videos
Remarkable Breakthroughs in the Treatment of Advanced NSCLC
03/22/2020
Martin J. Edelman, MD, discusses how the treatment landscape for advanced NSCLC has evolved in recent years.
Martin J. Edelman, MD, discusses how the treatment landscape for advanced NSCLC has evolved in recent years.
Martin J. Edelman, MD, discusses...
03/22/2020
Oncology
The Future of Lung Cancer Screening
Videos
The Future of Lung Cancer Screening
03/03/2020
James L. Mulshine, MD, talks about what the future holds vis-a-vis advancements in lung cancer screening.
James L. Mulshine, MD, talks about what the future holds vis-a-vis advancements in lung cancer screening.
James L. Mulshine, MD, talks...
03/03/2020
Oncology
The Role of Surgery in Locally Advanced NSCLC
Videos
The Role of Surgery in Locally Advanced NSCLC
02/26/2020
Jessica Donington, MD, discusses the role of surgery in managing patients with locally advanced NSCLC.
Jessica Donington, MD, discusses the role of surgery in managing patients with locally advanced NSCLC.
Jessica Donington, MD, discusses...
02/26/2020
Oncology
Videos
Fadi Braiteh, MD, Discusses the Ins and Outs of Entrectinib Therapy for NSCLC
12/03/2019
Dr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.
Dr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.
Dr Braiteh spoke in detail about...
12/03/2019
Oncology
Videos
The Evolving Treatment Landscape of Mesothelioma
12/02/2019
Jessica Donington, MD, talks about old approaches and new directions in the treatment of patients with mesothelioma.
Jessica Donington, MD, talks about old approaches and new directions in the treatment of patients with mesothelioma.
Jessica Donington, MD, talks...
12/02/2019
Oncology
Videos
Second-Line Therapies in the Treatment of NSCLC
12/01/2019
Edward B. Garon, MD, MS, discusses second-line therapies for the treatment of patients with NSCLC.
Edward B. Garon, MD, MS, discusses second-line therapies for the treatment of patients with NSCLC.
Edward B. Garon, MD, MS,...
12/01/2019
Oncology
Videos
Comparing Neoadjuvant vs Adjuvant Therapy for Early-Stage NSCLC
11/26/2019
Christine Ciunci, MD, MSCE, Penn Presbyterian Medical Center, spoke about the use of neoadjuvant versus adjuvant treatment in patients with early-stage NSCLC.
Christine Ciunci, MD, MSCE, Penn Presbyterian Medical Center, spoke about the use of neoadjuvant versus adjuvant treatment in patients with early-stage NSCLC.
Christine Ciunci, MD, MSCE, Penn...
11/26/2019
Oncology
Videos
Biomarkers for Immunotherapy in NSCLC
11/25/2019
Edward B. Garon, MD, MS, talks about biomarkers for immunotherapy use in patients with NSCLC.
Edward B. Garon, MD, MS, talks about biomarkers for immunotherapy use in patients with NSCLC.
Edward B. Garon, MD, MS, talks...
11/25/2019
Oncology
Videos
Joshua Bauml, MD, Discusses the Use of Brigatinib Therapy for ALK-Positive NSCLC
11/24/2019
Dr Bauml talks about the use of brigatinib in the treatment of patients with ALK-positive NSCLC.
Dr Bauml talks about the use of brigatinib in the treatment of patients with ALK-positive NSCLC.
Dr Bauml talks about the use of...
11/24/2019
Oncology
Videos
Puneeth Iyengar, MD, PhD, Talks Pros and Cons of Proton Therapy for Stage III NSCLC
11/24/2019
Dr Iyengar discusses the pros and cons of using proton therapy in the management of patients with stage III NSCLC.
Dr Iyengar discusses the pros and cons of using proton therapy in the management of patients with stage III NSCLC.
Dr Iyengar discusses the pros...
11/24/2019
Oncology
Videos
Approaches in the Frontline Treatment of EGFR-Positive NSCLC
11/24/2019
Edward B. Garon, MD, MS, discusses current approaches for the first-line treatment of patients with EGFR-positive NSCLC.
Edward B. Garon, MD, MS, discusses current approaches for the first-line treatment of patients with EGFR-positive NSCLC.
Edward B. Garon, MD, MS,...
11/24/2019
Oncology
Videos
New Innovations in Screening for NSCLC
11/24/2019
James L. Mulshine, MD, discusses novel techniques in the detection of early-stage NSCLC.
James L. Mulshine, MD, discusses novel techniques in the detection of early-stage NSCLC.
James L. Mulshine, MD, discusses...
11/24/2019
Oncology
Videos
Immunotherapy With or Without Chemo for the First-Line Treatment of NSCLC
11/23/2019
Martin J. Edelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the use of immunotherapy with or without chemo in the first-line treatment of NSCLC.
Martin J. Edelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the use of immunotherapy with or without chemo in the first-line treatment of NSCLC.
Martin J. Edelman, MD, Fox Chase...
11/23/2019
Oncology
Videos
The Role of Liquid Biopsies in Thoracic Malignancies
11/22/2019
Jonathan Goldman, MD, discusses the role liquid biopsies play in the diagnosis and follow-up of patients with thoracic malignancies.
Jonathan Goldman, MD, discusses the role liquid biopsies play in the diagnosis and follow-up of patients with thoracic malignancies.
Jonathan Goldman, MD, discusses...
11/22/2019
Oncology
Videos
Managing Resistance to Third-Generation TKIs in NSCLC
11/22/2019
Lyudmila Bazhenova, MD, talks about understanding, preventing, and delaying EGFR-resistance in the era of osimertinib therapy.
Lyudmila Bazhenova, MD, talks about understanding, preventing, and delaying EGFR-resistance in the era of osimertinib therapy.
Lyudmila Bazhenova, MD, talks...
11/22/2019
Oncology
Videos
Exploring the Use of Entrectinib in NSCLC
11/08/2019
Stephen Liu, MD, discusses takeaway points from a Product Theater for entrectinib held at the 2019 Perspectives in Thoracic Oncology.
Stephen Liu, MD, discusses takeaway points from a Product Theater for entrectinib held at the 2019 Perspectives in Thoracic Oncology.
Stephen Liu, MD, discusses...
11/08/2019
Oncology
Podcasts
Behind the Scenes With Edward Garon, MD: Perspectives in Thoracic Oncology
11/01/2019
In this short podcast, Dr Garon takes us behind the scenes of the Perspectives in Thoracic Oncology meeting, now in its 24th year.
In this short podcast, Dr Garon takes us behind the scenes of the Perspectives in Thoracic Oncology meeting, now in its 24th year.
In this short podcast, Dr Garon...
11/01/2019
Oncology
Videos
Emerging Therapies in the Treatment of SCLC
10/25/2019
Stephen Liu, MD, discusses the integration of emerging therapies into the current treatment algorithm of SCLC.
Stephen Liu, MD, discusses the integration of emerging therapies into the current treatment algorithm of SCLC.
Stephen Liu, MD, discusses the...
10/25/2019
Oncology
Videos
Joshua Bauml, MD, Talks Management of Oligometastic Lung Cancer
10/19/2019
Dr Bauml discusses novel developments in the management of oligometastatic disease.
Dr Bauml discusses novel developments in the management of oligometastatic disease.
Dr Bauml discusses novel...
10/19/2019
Oncology
Interview
Paul Paik, MD, Discusses the Treatment Landscape of SCLC
10/19/2019
At the 2019 Perspectives in Thoracic Oncology meeting, Dr Paik discussed treatment advances made in recent years for squamous cell lung cancer.
At the 2019 Perspectives in Thoracic Oncology meeting, Dr Paik discussed treatment advances made in recent years for squamous cell lung cancer.
At the 2019 Perspectives in...
10/19/2019
Oncology
Quitting Smoking Yields Health Benefits Even After Lung Cancer Diagnosis
10/18/2019
“There are health benefits to smoking cessation even after a cancer diagnosis, regardless of stage or prognosis, namely improvement in cancer treatment outcomes, disease recurrence, and secondary cancers,” said Laura Jean Bierut, MD.
“There are health benefits to smoking cessation even after a cancer diagnosis, regardless of stage or prognosis, namely improvement in cancer treatment outcomes, disease recurrence, and secondary cancers,” said Laura Jean Bierut, MD.
“There are health benefits to...
10/18/2019
Oncology
Interview
Challenges of Molecular and Immune Testing in Lung Cancer, and Implications of Liquid Biopsies
10/17/2019
Marc Ladanyi, MD, talks about the use of molecular and immune testing and liquid biopsies in lung cancer.
Marc Ladanyi, MD, talks about the use of molecular and immune testing and liquid biopsies in lung cancer.
Marc Ladanyi, MD, talks about...
10/17/2019
Oncology
Interview
Approaches in Radiation for Locally Advanced NSCLC
10/15/2019
Abigail Berman, MD, MSCE, discusses radiation therapy approaches for locally advanced NSCLC.
Abigail Berman, MD, MSCE, discusses radiation therapy approaches for locally advanced NSCLC.
Abigail Berman, MD, MSCE,...
10/15/2019
Oncology
Interview
Joshua Bauml, MD, Shares Insight on the 2019 Perspectives in Thoracic Oncology Meeting
09/13/2019
Joshua Bauml, MD, discusses his contribution to the 2019 Perspectives in Thoracic Oncology Meeting.
Joshua Bauml, MD, discusses his contribution to the 2019 Perspectives in Thoracic Oncology Meeting.
Joshua Bauml, MD, discusses his...
09/13/2019
Oncology
Videos
Perspectives in Thoracic Oncology 2019: Chair Insights
09/09/2019
Corey J. Langer, MD, shares content previews and insights about the expert faculty presenting at this year's Perspectives in Thoracic Oncology meeting.
Corey J. Langer, MD, shares content previews and insights about the expert faculty presenting at this year's Perspectives in Thoracic Oncology meeting.
Corey J. Langer, MD, shares...
09/09/2019
Oncology
Videos
Abigail Berman, MD, Discusses the Role of Proton Therapy in NSCLC
10/31/2018
In this 3-part video series, Dr Berman provides and overview of the debate on photon versus proton radiotherapy for NSCLC and discusses the current treatment landscape for patients with this disease.
In this 3-part video series, Dr Berman provides and overview of the debate on photon versus proton radiotherapy for NSCLC and discusses the current treatment landscape for patients with this disease.
In this 3-part video series, Dr...
10/31/2018
Oncology
Videos
Proton Versus Photon Radiotherapy: Factors to Consider
10/29/2018
Martin Edelman, MD, discusses biggest factors to consider in the debate about photon versus proton radiotherapy for patients with lung cancer.
Martin Edelman, MD, discusses biggest factors to consider in the debate about photon versus proton radiotherapy for patients with lung cancer.
Martin Edelman, MD, discusses...
10/29/2018
Oncology
Videos
Targeted Therapy and Immunotherapy Use in NSCLC
10/28/2018
Joshua Bauml, MD, spoke about the treatment options available for patients with NSCLC.
Joshua Bauml, MD, spoke about the treatment options available for patients with NSCLC.
Joshua Bauml, MD, spoke about...
10/28/2018
Oncology
Videos
James Mulshine, MD, Emphasizes the Importance of Lung Cancer Screening
10/24/2018
At the 23rd Annual Perspectives in Thoracic Oncology meeting, Dr Mulshine discussed the importance of lung cancer screening.
At the 23rd Annual Perspectives in Thoracic Oncology meeting, Dr Mulshine discussed the importance of lung cancer screening.
At the 23rd Annual Perspectives...
10/24/2018
Oncology
Osimertinib Is Still Standard First-Line Treatment for NSCLC With EGFR Mutation
10/13/2018
Osimertinib remains the standard approach for first line therapy in EGFR mutated NSCLC.
Osimertinib remains the standard approach for first line therapy in EGFR mutated NSCLC.
Osimertinib remains the standard...
10/13/2018
Oncology
Outcomes Better With Immune-Related Toxicities, Steroids Okay for Management
10/13/2018
Immune-related adverse events that occur with immunotherapies do not necessarily lead to worse outcomes in patients with cancer, and can be controlled with steroids.
Immune-related adverse events that occur with immunotherapies do not necessarily lead to worse outcomes in patients with cancer, and can be controlled with steroids.
Immune-related adverse events...
10/13/2018
Oncology
Alectinib Maintains First-Line Therapy Status for ALK-Positive NSCLC
10/13/2018
For patients with NSCLC and ALK mutation, first-line therapy with alectinib is standard care, however, sequence of therapy is not so readily defined.
For patients with NSCLC and ALK mutation, first-line therapy with alectinib is standard care, however, sequence of therapy is not so readily defined.
For patients with NSCLC and ALK...
10/13/2018
Oncology
Manage Patient Expectations by Simplifying Communication, Strengthening Trust
10/12/2018
Beth Eaby-Sandy, MSN, CRNP, discusses the importance of simplifying discussions and facilitating open dialogues with patients when discussing their treatment expectations.
Beth Eaby-Sandy, MSN, CRNP, discusses the importance of simplifying discussions and facilitating open dialogues with patients when discussing their treatment expectations.
Beth Eaby-Sandy, MSN, CRNP,...
10/12/2018
Oncology
Smoking Cessation is Key but E-Cigarettes are Less Toxic, Preferable to Combustible Cigarettes
10/12/2018
Laura Jean Bierut, MD, makes it clear that while it is never too late for a clinician to encourage a patient to stop smoking, e-cigarettes may not be the worst fallback for cigarette smokers.
Laura Jean Bierut, MD, makes it clear that while it is never too late for a clinician to encourage a patient to stop smoking, e-cigarettes may not be the worst fallback for cigarette smokers.
Laura Jean Bierut, MD, makes it...
10/12/2018
Oncology
Liquid Biopsies Improve Delivery of Targeted Therapy in Metastatic NSCLC
10/12/2018
Adding a liquid biopsy to standard care tumor surveillance led to a marked increase in the detection of mutations that can be targeted with therapy, a recent study has shown.
Adding a liquid biopsy to standard care tumor surveillance led to a marked increase in the detection of mutations that can be targeted with therapy, a recent study has shown.
Adding a liquid biopsy to...
10/12/2018
Oncology

Advertisement

About

Formerly known as Perspectives in Thoracic Oncology, the lung cancer meeting you know and love is getting a makeover. With an updated name to reflect a more pronounced focus on targeted therapies, biomarker testing and precision medicine, year 25 of this educational gathering is getting practical. Personalized Therapies in Thoracic Oncology will go beyond chemotherapy and focus on the best way to treat your patients when traditional methods aren't cutting it. 

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement